PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.
Kauko O, O'Connor CM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S, Yetukuri L, Yadav B, Padzik A, Laajala TD, Haapaniemi P, Momeny M, Varila T, Ohlmeyer M, Aittokallio T, Wennerberg K, Narla G, Westermarck J.
Kauko O, et al. Among authors: yadav b.
Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. doi: 10.1126/scitranslmed.aaq1093.
Sci Transl Med. 2018.
PMID: 30021885
Free PMC article.